- Home
- FRD vs ATOS Comparison
FRD vs ATOS Comparison
Compare FRD & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRD
- ATOS
- Stock Information
- Founded
- FRD 1965
- ATOS 2009
- Country
- FRD United States
- ATOS United States
- Employees
- FRD N/A
- ATOS N/A
- Industry
- FRD Steel/Iron Ore
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- FRD Industrials
- ATOS Health Care
- Exchange
- FRD Nasdaq
- ATOS Nasdaq
- Market Cap
- FRD 122.0M
- ATOS 114.5M
- IPO Year
- FRD N/A
- ATOS 2012
- Fundamental
- Price
- FRD $16.82
- ATOS $0.80
- Analyst Decision
- FRD
- ATOS Strong Buy
- Analyst Count
- FRD 0
- ATOS 3
- Target Price
- FRD N/A
- ATOS $7.00
- AVG Volume (30 Days)
- FRD 17.4K
- ATOS 678.1K
- Earning Date
- FRD 02-07-2025
- ATOS 03-31-2025
- Dividend Yield
- FRD 0.95%
- ATOS N/A
- EPS Growth
- FRD N/A
- ATOS N/A
- EPS
- FRD 0.81
- ATOS N/A
- Revenue
- FRD $447,616,000.00
- ATOS N/A
- Revenue This Year
- FRD N/A
- ATOS N/A
- Revenue Next Year
- FRD N/A
- ATOS N/A
- P/E Ratio
- FRD $20.68
- ATOS N/A
- Revenue Growth
- FRD N/A
- ATOS N/A
- 52 Week Low
- FRD $13.40
- ATOS $0.72
- 52 Week High
- FRD $19.52
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- FRD 59.84
- ATOS 41.00
- Support Level
- FRD $16.62
- ATOS $0.79
- Resistance Level
- FRD $17.69
- ATOS $0.89
- Average True Range (ATR)
- FRD 0.79
- ATOS 0.05
- MACD
- FRD 0.05
- ATOS 0.01
- Stochastic Oscillator
- FRD 66.78
- ATOS 25.14
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.